Back to Agenda
Session 2C (Clinical Development Track): Non-Liver Targets
Session Chair(s)
Peter S. Miele, MD
Medical Officer, Division of Antiviral Products, OND, OMPT, OAP, CDER
FDA, United States
James D. Thompson, PhD
Vice President, Pharmaceutical Development
Quark Pharmaceuticals Inc., United States
Clinical update for nonhepatic targets. While many oligonucleotide therapeutics target the liver to exploit the propensity of hepatic delivery, a substantial number of clinical programs aim at non-hepatic targets for activity. Viral replication has always been a prime candidate for therapeutic intervention with oligonucleotide therapeutics. In fact the first antisense oligonucleotides in clinical trials and the first to be approved targeted viral replication. In this session two of the talks describe more recent efforts to use siRNA to inhibit viral replication: one with a locally delivered siRNA and the other with a systemically delivered siRNA targeting the Ebola virus.
Speaker(s)
Phase 2 Data on ALN-RSV01 for the Treatment of Bronchiolitis Obliterans Syndrome in RSV-infected Lung Transplant Patients
Jared A. Gollob, MD
Alnylam Pharmaceuticals, Inc., United States
Vice President, Clinical Research
Ebola
Ian MacLachlan, PhD
Tekmira Pharmaceuticals Corporation, Canada
Executive Vice President and Chief Scientific Officer
iCo-007 in Treatment of Diabetic Macular Edema
Peter Hnik, MD
iCo Therapeutics, Inc., Canada
Chief Medical Officer
Have an account?